Meet Katherine

katherine

Katherine Spacek is the mother of Brock, 7, who has severe hemophilia A with an inhibitor. When Brock was born, his neonatal team noticed that something was not right—he was bleeding excessively. After a series of tests, Brock was diagnosed with his bleeding disorder. He was two days old. Brock’s parents never suspected hemophilia, as there was no family history of hemophilia on either side.

Want to learn more about Katherine and her son, Brock? Sign up for
Mom2Mom E-News and you’ll be notified when Katherine has a new story! It only takes a minute to sign up, and you’ll get reminders whenever hemophiliamoms.com has a new featured mom’s story, article, or other updates! Sign up now!

Helixatefs.com

Important Safety Information for Helixate^®FS

Helixate^® FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor.

Helixate^® FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations of known sensitivity to mouse or hamster protein.

Adverse events are generally minor. The most common adverse events include injection-site reactions, dizziness, and rash.

For more information about Helixate^® FS, please see full Prescribing Information.